Abstract
Breast cancer is a first magnitude problem of public health worldwide. There is increasing evidence that this cancer is originated in and maintained by a small population of undifferentiated cells with self-renewal properties. This small population generates a more differentiated pool of cells which represents the main mass of the tumor, resembling the hierarchical tissue organization of the normal breast. These cancer stem cells seem to share a similar phenotype with their normal counterparts but they display dysfunctional patterns of proliferation and differentiation, and they no longer respond to normal physiological controls that ensure a balanced cellular turnover. The origin of these cancer stem cells is controversial; it is not well known if they are originated from normal stem cells or from more differentiated progenitors where a de novo stem cell program is activated by the oncogenic insult. Here we review the origin of breast cancer stem cells and their role in the pathogenesis of cancer development, together with their implications in breast cancer progression, treatment and prognosis.
Keywords: Stem cell, breast cancer, self-renewal, hierarchy, progenitor
Current Stem Cell Research & Therapy
Title: Breast Cancer, a Stem Cell Disease
Volume: 3 Issue: 1
Author(s): Jesus Perez-Losada and Rogelio Gonzalez-Sarmiento
Affiliation:
Keywords: Stem cell, breast cancer, self-renewal, hierarchy, progenitor
Abstract: Breast cancer is a first magnitude problem of public health worldwide. There is increasing evidence that this cancer is originated in and maintained by a small population of undifferentiated cells with self-renewal properties. This small population generates a more differentiated pool of cells which represents the main mass of the tumor, resembling the hierarchical tissue organization of the normal breast. These cancer stem cells seem to share a similar phenotype with their normal counterparts but they display dysfunctional patterns of proliferation and differentiation, and they no longer respond to normal physiological controls that ensure a balanced cellular turnover. The origin of these cancer stem cells is controversial; it is not well known if they are originated from normal stem cells or from more differentiated progenitors where a de novo stem cell program is activated by the oncogenic insult. Here we review the origin of breast cancer stem cells and their role in the pathogenesis of cancer development, together with their implications in breast cancer progression, treatment and prognosis.
Export Options
About this article
Cite this article as:
Perez-Losada Jesus and Gonzalez-Sarmiento Rogelio, Breast Cancer, a Stem Cell Disease, Current Stem Cell Research & Therapy 2008; 3 (1) . https://dx.doi.org/10.2174/157488808783489453
DOI https://dx.doi.org/10.2174/157488808783489453 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Modulators of TRP Channels
Current Topics in Medicinal Chemistry Propargyl 4-[18F]fluorobenzoate: A Putatively More Stable Prosthetic Group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry
Current Radiopharmaceuticals Vitamin D Analogs- Drug Design Based on Proteins Involved in Vitamin D Signal Transduction
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Activation of the dsRNA-Activated Protein Kinase PKR in Mitochondrial Dysfunction and Inflammatory Stress in Metabolic Syndrome
Current Pharmaceutical Design Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer
Current Drug Targets From TGF-β to Cancer Therapy
Current Drug Targets Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Comparative Studies of the Chromogranin A-Derived Neuropeptide WE-14
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry Editorial [Hot topic: Target Therapy of Bone Metastases and Tumours (Guest Editors: M. Caraglia and D. Santini)]
Current Cancer Drug Targets Identification of Quinolone and Colistin Resistance Genes in <i>Escherichia Coli</i> Strains Isolated from Mucosal Samples of Patients with Colorectal Cancer and Healthy Subjects
Recent Patents on Anti-Infective Drug Discovery Alternative Medicine as a Treatment Option for COVID-19
Current Traditional Medicine Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Synthetic Spirocyclohexadienones as New Anti-Migratory Compounds in Triple- Negative Breast Cancer Cell Migration
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition Heterocyclic Compounds as MDR Modulators
Letters in Drug Design & Discovery Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets